Discovery of First-in-Class TAK1–MKK3 Protein–Protein Interaction (PPI) Inhibitor <b>(<i>R</i>)-STU104</b> for the Treatment of Ulcerative Colitis through Modulating TNF-α Production
作者:Mei-Lin Tang、Haidong Li、Jin-Feng Ning、Xiaoyan Shen、Xun Sun
DOI:10.1021/acs.jmedchem.1c02198
日期:2022.5.12
therapeutic target for autoimmune diseases. However, this biological therapy exhibits some inevitable disadvantages, such as risk of infection. Thus, small-molecule alternatives by targeting TNF-α production signaling pathway are still in demand. Herein, we describe the design, synthesis, and structure–activity relationships of 3-aryindanone compounds regarding their modulation of TNF-α production. Among
肿瘤坏死因子α(TNF-α)已被证明是自身免疫性疾病的治疗靶点。然而,这种生物疗法表现出一些不可避免的缺点,例如感染风险。因此,仍然需要通过靶向 TNF-α 产生信号通路的小分子替代品。在此,我们描述了 3-芳基茚满酮化合物在调节 TNF-α 产生方面的设计、合成和构效关系。其中,( R )-STU104对TNF-α产生的抑制活性最强,它通过与MKK3结合并破坏TAK1磷酸化MKK3来抑制TAK1/MKK3/p38/MnK1/MK2/elF4E信号通路。结果,( R )-STU104在急性和慢性小鼠 UC 模型中表现出显着的剂量效应关系。除了其良好的药代动力学 (PK) 和安全性外,( R )-STU104在 10 mg/kg/d的体内抗 UC 疗效优于50 mg/kg/d 的美沙拉嗪。这些结果表明 TAK1-MKK3 相互作用抑制剂可潜在地用于治疗 UC。